246 related articles for article (PubMed ID: 32963047)
1. A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis.
Allanore Y; Wung P; Soubrane C; Esperet C; Marrache F; Bejuit R; Lahmar A; Khanna D; Denton CP;
Ann Rheum Dis; 2020 Dec; 79(12):1600-1607. PubMed ID: 32963047
[TBL] [Abstract][Full Text] [Related]
2. Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial.
Khanna D; Allanore Y; Denton CP; Kuwana M; Matucci-Cerinic M; Pope JE; Atsumi T; Bečvář R; Czirják L; Hachulla E; Ishii T; Ishikawa O; Johnson SR; De Langhe E; Stagnaro C; Riccieri V; Schiopu E; Silver RM; Smith V; Steen V; Stevens W; Szücs G; Truchetet ME; Wosnitza M; Laapas K; de Oliveira Pena J; Yao Z; Kramer F; Distler O
Ann Rheum Dis; 2020 May; 79(5):618-625. PubMed ID: 32299845
[TBL] [Abstract][Full Text] [Related]
3. SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772).
Raghu G; Richeldi L; Crestani B; Wung P; Bejuit R; Esperet C; Antoni C; Soubrane C
Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30337444
[TBL] [Abstract][Full Text] [Related]
4. Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial.
Mantero JC; Kishore N; Ziemek J; Stifano G; Zammitti C; Khanna D; Gordon JK; Spiera R; Zhang Y; Simms RW; Lafyatis R
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):146-149. PubMed ID: 30277862
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.
Postlethwaite AE; Wong WK; Clements P; Chatterjee S; Fessler BJ; Kang AH; Korn J; Mayes M; Merkel PA; Molitor JA; Moreland L; Rothfield N; Simms RW; Smith EA; Spiera R; Steen V; Warrington K; White B; Wigley F; Furst DE
Arthritis Rheum; 2008 Jun; 58(6):1810-22. PubMed ID: 18512816
[TBL] [Abstract][Full Text] [Related]
6. Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial.
Gordon JK; Martyanov V; Franks JM; Bernstein EJ; Szymonifka J; Magro C; Wildman HF; Wood TA; Whitfield ML; Spiera RF
Arthritis Rheumatol; 2018 Feb; 70(2):308-316. PubMed ID: 29073351
[TBL] [Abstract][Full Text] [Related]
7. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Khanna D; Lin CJF; Furst DE; Goldin J; Kim G; Kuwana M; Allanore Y; Matucci-Cerinic M; Distler O; Shima Y; van Laar JM; Spotswood H; Wagner B; Siegel J; Jahreis A; Denton CP;
Lancet Respir Med; 2020 Oct; 8(10):963-974. PubMed ID: 32866440
[TBL] [Abstract][Full Text] [Related]
8. Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis.
Chakravarty EF; Martyanov V; Fiorentino D; Wood TA; Haddon DJ; Jarrell JA; Utz PJ; Genovese MC; Whitfield ML; Chung L
Arthritis Res Ther; 2015 Jun; 17(1):159. PubMed ID: 26071192
[TBL] [Abstract][Full Text] [Related]
9. Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
Khanna D; Spino C; Johnson S; Chung L; Whitfield ML; Denton CP; Berrocal V; Franks J; Mehta B; Molitor J; Steen VD; Lafyatis R; Simms RW; Gill A; Kafaja S; Frech TM; Hsu V; Domsic RT; Pope JE; Gordon JK; Mayes MD; Schiopu E; Young A; Sandorfi N; Park J; Hant FN; Bernstein EJ; Chatterjee S; Castelino FV; Ajam A; Wang Y; Wood T; Allanore Y; Matucci-Cerinic M; Distler O; Singer O; Bush E; Fox DA; Furst DE
Arthritis Rheumatol; 2020 Jan; 72(1):125-136. PubMed ID: 31342624
[TBL] [Abstract][Full Text] [Related]
10. Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial.
Quillinan NP; McIntosh D; Vernes J; Haq S; Denton CP
Ann Rheum Dis; 2014 Jan; 73(1):56-61. PubMed ID: 24067785
[TBL] [Abstract][Full Text] [Related]
11. Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension Study.
Allanore Y; Distler O; Jagerschmidt A; Illiano S; Ledein L; Boitier E; Agueusop I; Denton CP; Khanna D
Arthritis Rheumatol; 2018 Oct; 70(10):1634-1643. PubMed ID: 29732731
[TBL] [Abstract][Full Text] [Related]
12. Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.
Pope J; McBain D; Petrlich L; Watson S; Vanderhoek L; de Leon F; Seney S; Summers K
Arthritis Rheum; 2011 Nov; 63(11):3547-51. PubMed ID: 21769850
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis.
Takehara K; Ihn H; Sato S
Clin Exp Rheumatol; 2013; 31(2 Suppl 76):151-6. PubMed ID: 23910617
[TBL] [Abstract][Full Text] [Related]
14. RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis.
Distler O; Pope J; Denton C; Allanore Y; Matucci-Cerinic M; de Oliveira Pena J; Khanna D
Respir Med; 2017 Jan; 122 Suppl 1():S14-S17. PubMed ID: 27746061
[TBL] [Abstract][Full Text] [Related]
15. A 24-Week, Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis.
Khanna D; Denton CP; Furst DE; Mayes MD; Matucci-Cerinic M; Smith V; de Vries D; Ford P; Bauer Y; Randall MJ; Ebrahimpoor M; Kupcsik L; Stiers PJ; Deberdt L; Prasad N; Lim S; Pujuguet P; Ahmed S
Arthritis Rheumatol; 2023 Aug; 75(8):1434-1444. PubMed ID: 36787101
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial.
Chung L; Spino C; McLain R; Johnson SR; Denton CP; Molitor JA; Steen VD; Lafyatis R; Simms RW; Kafaja S; Frech TM; Hsu V; Domsic RT; Pope JE; Gordon JK; Mayes MD; Sandorfi N; Hant FN; Bernstein EJ; Chatterjee S; Castelino FV; Ajam A; Allanore Y; Matucci-Cerinic M; Whitfield ML; Distler O; Singer O; Young A; Nagaraja V; Fox DA; Furst DE; Khanna D
Lancet Rheumatol; 2020 Dec; 2(12):e743-e753. PubMed ID: 34966900
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.
Prey S; Ezzedine K; Doussau A; Grandoulier AS; Barcat D; Chatelus E; Diot E; Durant C; Hachulla E; de Korwin-Krokowski JD; Kostrzewa E; Quemeneur T; Paul C; Schaeverbeke T; Seneschal J; Solanilla A; Sparsa A; Bouchet S; Lepreux S; Mahon FX; Chene G; Taïeb A
Br J Dermatol; 2012 Nov; 167(5):1138-44. PubMed ID: 23039171
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease.
Boulos D; Ngian GS; Rajadurai A; Elford K; Stevens W; Proudman S; Owen C; Roddy J; Nikpour M; Youssef P; Hill C; Sahhar J
Int J Rheum Dis; 2017 Apr; 20(4):481-488. PubMed ID: 28337853
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).
Khanna D; Denton CP; Lin CJF; van Laar JM; Frech TM; Anderson ME; Baron M; Chung L; Fierlbeck G; Lakshminarayanan S; Allanore Y; Pope JE; Riemekasten G; Steen V; Müller-Ladner U; Spotswood H; Burke L; Siegel J; Jahreis A; Furst DE
Ann Rheum Dis; 2018 Feb; 77(2):212-220. PubMed ID: 29066464
[TBL] [Abstract][Full Text] [Related]
20. Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial.
Gordon JK; Martyanov V; Magro C; Wildman HF; Wood TA; Huang WT; Crow MK; Whitfield ML; Spiera RF
Arthritis Res Ther; 2015 Aug; 17(1):213. PubMed ID: 26283632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
